| Mutations of the BRAF gene in human cancer H Davies, GR Bignell, C Cox, P Stephens, S Edkins, S Clegg, J Teague, ... Nature 417 (6892), 949-954, 2002 | 12995 | 2002 |
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF PTC Wan, MJ Garnett, SM Roe, S Lee, D Niculescu-Duvaz, VM Good, ... Cell 116 (6), 855-867, 2004 | 3370 | 2004 |
| Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ... Nucleic acids research 41 (D1), D955-D961, 2012 | 3294 | 2012 |
| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2640 | 2012 |
| Prospective derivation of a living organoid biobank of colorectal cancer patients M Van de Wetering, HE Francies, JM Francis, G Bounova, F Iorio, A Pronk, ... Cell 161 (4), 933-945, 2015 | 2243 | 2015 |
| A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1883 | 2016 |
| Human primary liver cancer–derived organoid cultures for disease modeling and drug screening L Broutier, G Mastrogiovanni, MMA Verstegen, HE Francies, LM Gavarró, ... Nature medicine 23 (12), 1424-1435, 2017 | 1296 | 2017 |
| Guilty as charged: B-RAF is a human oncogene MJ Garnett, R Marais Cancer cell 6 (4), 313-319, 2004 | 1192 | 2004 |
| Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1146 | 2019 |
| Perturbation-response genes reveal signaling footprints in cancer gene expression M Schubert, B Klinger, M Klünemann, A Sieber, F Uhlitz, S Sauer, ... Nature communications 9 (1), 20, 2018 | 620 | 2018 |
| Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties MP Menden, F Iorio, M Garnett, U McDermott, CH Benes, PJ Ballester, ... PLoS one 8 (4), e61318, 2013 | 571 | 2013 |
| Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization MJ Garnett, S Rana, H Paterson, D Barford, R Marais Molecular cell 20 (6), 963-969, 2005 | 518 | 2005 |
| MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ... Cell 151 (5), 937-950, 2012 | 498 | 2012 |
| A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ... Cell 167 (1), 260-274. e22, 2016 | 471 | 2016 |
| High-content CRISPR screening C Bock, P Datlinger, F Chardon, MA Coelho, MB Dong, KA Lawson, T Lu, ... Nature Reviews Methods Primers 2 (1), 1-23, 2022 | 444 | 2022 |
| ETV6-NTRK3 Gene Fusions and Trisomy 11 Establish a Histogenetic Link between Mesoblastic Nephroma and Congenital Fibrosarcoma SR Knezevich, MJ Garnett, TJ Pysher, JB Beckwith, PE Grundy, ... Cancer research 58 (22), 5046-5048, 1998 | 439 | 1998 |
| Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis M Petljak, LB Alexandrov, JS Brammeld, S Price, DC Wedge, ... Cell 176 (6), 1282-1294. e20, 2019 | 397 | 2019 |
| Pancreatic cancer organoids recapitulate disease and allow personalized drug screening E Driehuis, A Van Hoeck, K Moore, S Kolders, HE Francies, ... Proceedings of the National Academy of Sciences 116 (52), 26580-26590, 2019 | 390 | 2019 |
| Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics X Li, HE Francies, M Secrier, J Perner, A Miremadi, N Galeano-Dalmau, ... Nature communications 9 (1), 2983, 2018 | 313 | 2018 |
| Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ... Nature communications 10 (1), 2674, 2019 | 310 | 2019 |
Ultan McDermottChief Scientist, Oncology R&D, AstraZenecaEmail verificata su astrazeneca.com